Ana Arrobas

TL;DR: The Portuguese Severe Asthma Registry (RAG) is a national web-based disease registry of severe asthma patients that allows prospective clinical data collection, promotes standardized care and collaborative clinical research, and may contribute to inform evidence-based healthcare policies for severe asthma.

TL;DR: Although both patients and physicians report high inhaler adherence, discordance occurred in half of cases, implementation of objective adherence measures and effective communication are needed to improve patient-physician agreement.

TL;DR: Patients with severe asthma, uncontrolled besides optimal treatment, notwithstanding nonatopic, may also benefit from omalizumab therapy, although currently there are no randomized double-blind placebo controlled clinical trials to support this suggestion.

TL;DR: During routine treatment with omalizumab, Portuguese patients with severe asthma achieved asthma control in 1/3 of the visits and only one-third of the patients needed unscheduled or Emergency Room care because of asthma exacerbations, which support the maintenance of the clinical effect during treatment with OmalIZumab in routine care in Portugal.

TL;DR: The InspirerMundi app was feasible and acceptable to monitor medication adherence in patients with asthma and patients were globally satisfied with the app, with adherence monitoring, symptom monitoring, and gamification features being the most highly scored components; and the medication detection tool among the lowest scored.